Retinal vascular oximetry during ranibizumab treatment of central retinal vein occlusion

Sindri Traustason; Morten la Cour; Michael Larsen

doi:10.1136/bjophthalmol-2013-304580

Retinal vascular oximetry during ranibizumab treatment of central retinal vein occlusion

Sindri Traustason, Morten la Cour, Michael Larsen

Department of Clinical Medicine

29 Citations (Scopus)

Abstract

Purpose: To investigate the effect of intravitreal injections of the vascular endothelial growth factor inhibitor ranibizumab on retinal oxygenation in patients with central retinal vein occlusion (CRVO). Methods: Retinal oxygen saturation in patients with CRVO was analysed using the Oxymap Retinal Oximeter P3, before and during 6 months of treatment with intravitreal injections of ranibizumab. Results: At presentation, retinal venous oxygen saturation was lower in eyes with CRVO than in the healthy fellow eyes (32±13% vs 59±10%, respectively, p=0.001) whereas retinal arterial saturation was higher in eyes with CRVO than in the fellow eyes (95%±8% and 91%±3%, p=0.04). Mean visual acuity increased from 51±24 letters ETDRS at baseline to 66±24 and 69±20 letters ETRDS, respectively, at 3 months and 6 months treatment (mean±SD, p<0.0001, repeated measures analysis of variance) and central retinal thickness was reduced from 697±139 μm to 368 ±113 μm and 340±96 μm, respectively, from baseline to 3 months and 6 months treatment (p<0.0001). Venous saturation increased during treatment (from 35.5%±13.8% at baseline to 43.1%±10.8% and 43.5%±13.7% after 3 months and 6 months treatment, respectively, p=0.012), while no significant change was found in arterial saturation ( p=0.24). Conclusions: Retinal venous oxygen saturation was markedly reduced in untreated CRVO and was roughly halfway normalised during intravitreal ranibizumab treatment. Retinal artery oxygen saturation was not reduced in CRVO. Trial registration number: NCT01360385.

Original language	English
Journal	British Journal of Ophthalmology
Volume	98
Issue number	9
Pages (from-to)	1208-1211
Number of pages	4
ISSN	0007-1161
DOIs	https://doi.org/10.1136/bjophthalmol-2013-304580
Publication status	Published - Sept 2014

Keywords

Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Drug Administration Schedule
Female
Humans
Intravitreal Injections
Male
Middle Aged
Oximetry
Oxygen
Prospective Studies
Retinal Artery
Retinal Vein
Retinal Vein Occlusion
Tomography, Optical Coherence
Vascular Endothelial Growth Factor A
Visual Acuity

Access to Document

10.1136/bjophthalmol-2013-304580

Cite this

@article{505f33b518da40469cd75bfdb7f4ddcb,

title = "Retinal vascular oximetry during ranibizumab treatment of central retinal vein occlusion",

abstract = "Purpose: To investigate the effect of intravitreal injections of the vascular endothelial growth factor inhibitor ranibizumab on retinal oxygenation in patients with central retinal vein occlusion (CRVO). Methods: Retinal oxygen saturation in patients with CRVO was analysed using the Oxymap Retinal Oximeter P3, before and during 6 months of treatment with intravitreal injections of ranibizumab. Results: At presentation, retinal venous oxygen saturation was lower in eyes with CRVO than in the healthy fellow eyes (32±13% vs 59±10%, respectively, p=0.001) whereas retinal arterial saturation was higher in eyes with CRVO than in the fellow eyes (95%±8% and 91%±3%, p=0.04). Mean visual acuity increased from 51±24 letters ETDRS at baseline to 66±24 and 69±20 letters ETRDS, respectively, at 3 months and 6 months treatment (mean±SD, p<0.0001, repeated measures analysis of variance) and central retinal thickness was reduced from 697±139 μm to 368 ±113 μm and 340±96 μm, respectively, from baseline to 3 months and 6 months treatment (p<0.0001). Venous saturation increased during treatment (from 35.5%±13.8% at baseline to 43.1%±10.8% and 43.5%±13.7% after 3 months and 6 months treatment, respectively, p=0.012), while no significant change was found in arterial saturation ( p=0.24). Conclusions: Retinal venous oxygen saturation was markedly reduced in untreated CRVO and was roughly halfway normalised during intravitreal ranibizumab treatment. Retinal artery oxygen saturation was not reduced in CRVO. Trial registration number: NCT01360385.",

keywords = "Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Drug Administration Schedule, Female, Humans, Intravitreal Injections, Male, Middle Aged, Oximetry, Oxygen, Prospective Studies, Retinal Artery, Retinal Vein, Retinal Vein Occlusion, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A, Visual Acuity",

author = "Sindri Traustason and {la Cour}, Morten and Michael Larsen",

note = "Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.",

year = "2014",

month = sep,

doi = "10.1136/bjophthalmol-2013-304580",

language = "English",

volume = "98",

pages = "1208--1211",

journal = "British Journal of Ophthalmology",

issn = "0007-1161",

publisher = "B M J Group",

number = "9",

}

TY - JOUR

T1 - Retinal vascular oximetry during ranibizumab treatment of central retinal vein occlusion

AU - Traustason, Sindri

AU - la Cour, Morten

AU - Larsen, Michael

N1 - Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

PY - 2014/9

Y1 - 2014/9

N2 - Purpose: To investigate the effect of intravitreal injections of the vascular endothelial growth factor inhibitor ranibizumab on retinal oxygenation in patients with central retinal vein occlusion (CRVO). Methods: Retinal oxygen saturation in patients with CRVO was analysed using the Oxymap Retinal Oximeter P3, before and during 6 months of treatment with intravitreal injections of ranibizumab. Results: At presentation, retinal venous oxygen saturation was lower in eyes with CRVO than in the healthy fellow eyes (32±13% vs 59±10%, respectively, p=0.001) whereas retinal arterial saturation was higher in eyes with CRVO than in the fellow eyes (95%±8% and 91%±3%, p=0.04). Mean visual acuity increased from 51±24 letters ETDRS at baseline to 66±24 and 69±20 letters ETRDS, respectively, at 3 months and 6 months treatment (mean±SD, p<0.0001, repeated measures analysis of variance) and central retinal thickness was reduced from 697±139 μm to 368 ±113 μm and 340±96 μm, respectively, from baseline to 3 months and 6 months treatment (p<0.0001). Venous saturation increased during treatment (from 35.5%±13.8% at baseline to 43.1%±10.8% and 43.5%±13.7% after 3 months and 6 months treatment, respectively, p=0.012), while no significant change was found in arterial saturation ( p=0.24). Conclusions: Retinal venous oxygen saturation was markedly reduced in untreated CRVO and was roughly halfway normalised during intravitreal ranibizumab treatment. Retinal artery oxygen saturation was not reduced in CRVO. Trial registration number: NCT01360385.

AB - Purpose: To investigate the effect of intravitreal injections of the vascular endothelial growth factor inhibitor ranibizumab on retinal oxygenation in patients with central retinal vein occlusion (CRVO). Methods: Retinal oxygen saturation in patients with CRVO was analysed using the Oxymap Retinal Oximeter P3, before and during 6 months of treatment with intravitreal injections of ranibizumab. Results: At presentation, retinal venous oxygen saturation was lower in eyes with CRVO than in the healthy fellow eyes (32±13% vs 59±10%, respectively, p=0.001) whereas retinal arterial saturation was higher in eyes with CRVO than in the fellow eyes (95%±8% and 91%±3%, p=0.04). Mean visual acuity increased from 51±24 letters ETDRS at baseline to 66±24 and 69±20 letters ETRDS, respectively, at 3 months and 6 months treatment (mean±SD, p<0.0001, repeated measures analysis of variance) and central retinal thickness was reduced from 697±139 μm to 368 ±113 μm and 340±96 μm, respectively, from baseline to 3 months and 6 months treatment (p<0.0001). Venous saturation increased during treatment (from 35.5%±13.8% at baseline to 43.1%±10.8% and 43.5%±13.7% after 3 months and 6 months treatment, respectively, p=0.012), while no significant change was found in arterial saturation ( p=0.24). Conclusions: Retinal venous oxygen saturation was markedly reduced in untreated CRVO and was roughly halfway normalised during intravitreal ranibizumab treatment. Retinal artery oxygen saturation was not reduced in CRVO. Trial registration number: NCT01360385.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Angiogenesis Inhibitors

KW - Antibodies, Monoclonal, Humanized

KW - Drug Administration Schedule

KW - Female

KW - Humans

KW - Intravitreal Injections

KW - Male

KW - Middle Aged

KW - Oximetry

KW - Oxygen

KW - Prospective Studies

KW - Retinal Artery

KW - Retinal Vein

KW - Retinal Vein Occlusion

KW - Tomography, Optical Coherence

KW - Vascular Endothelial Growth Factor A

KW - Visual Acuity

U2 - 10.1136/bjophthalmol-2013-304580

DO - 10.1136/bjophthalmol-2013-304580

M3 - Journal article

C2 - 24729079

SN - 0007-1161

VL - 98

SP - 1208

EP - 1211

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

IS - 9

ER -

Retinal vascular oximetry during ranibizumab treatment of central retinal vein occlusion

Abstract

Keywords

Access to Document

Fingerprint

Cite this